Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 704 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CC5013 Clear all

Conditions: Multiple Myeloma
Interventions: Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 7
States / cities: Miami, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more

Conditions: Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Interventions: Ibrutinib, Lenalidomide, Rituximab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Doxil; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Multiple Myeloma
Interventions: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg, Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Lenalidomide, Ibrutinib, Rituximab; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pancreatic Cancer
Interventions: CC-5013, gemcitabine; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: Metairie, Louisiana • St Louis, Missouri • Cleveland, Ohio + 3 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Daratumumab/rHuPH20; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2040
U.S. locations: 837
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: CC-122, Ibrutinib, Obinutuzumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more

Conditions: Multiple Myeloma
Interventions: Revlimid; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia
Interventions: Eltrombopag Olamine, Laboratory Biomarker Analysis, Lenalidomide; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: Kansas City, Kansas • The Bronx, New York

Conditions: Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome, Recurrent Transformed Mycosis Fungoides, Refractory Mycosis Fungoides, Refractory Sezary Syndrome, Refractory Transformed Mycosis Fungoides, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Cosibelimab, Lenalidomide, Positron Emission Tomography, Questionnaire Administration, Skin Biopsy; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • Palm Springs, California + 15 more

Conditions: Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
Interventions: Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis, Lenalidomide; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 507
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 345 more

Conditions: Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions: Ibrutinib, Lenalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Columbus, Ohio

Conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions: Teclistamab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Irene Ghobrial, MD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 3
States / cities: Denver, Colorado • Boston, Massachusetts • Portland, Oregon

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Pomalidomide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Bendamustine, Rituximab, Lenalidomide; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 10
States / cities: Green Bay, Wisconsin • Janesville, Wisconsin • La Crosse, Wisconsin + 6 more

Conditions: Multiple Myeloma
Interventions: Iberdomide, Lenalidomide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 44
States / cities: Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Rituximab, Fludarabine, Lenalidomide; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Lymphocytic Leukemia, CLL
Interventions: Revlimid, Rituximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Neuropathy, Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
Interventions: Lenalidomide; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Multiple Myeloma
Interventions: Daratumumab IV, Lenalidomide, Dexamethasone, Daratumumab SC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 737 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 80 more

Conditions: Prostate Cancer
Interventions: Revlimid; Drug
Lead sponsor: Oncology Specialists, S.C.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Niles, Illinois • Park Ridge, Illinois

Conditions: Hematologic Disorder
Interventions: Lenalidomide, Influenza Vaccine, Pneumovax Vaccine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study of Daratumumab

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Dasatinib in Combination With Revlimid (and Dexamethasone)

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)